{
  "_id": "NCT00133328",
  "title": "A Morbidity-Mortality and Remodeling Study With Valsartan",
  "text": "Summary: The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker (ARB), in addition to conventional treatment, will improve the prognosis of 3000 Japanese patients with cardiovascular diseases.\nInclusion criteria: inclusion criteria: \n\n Clinical diagnosis of hypertension, ischemic heart disease and congestive heart failure \n\n \nExclusion criteria: : \n\n Pregnancy \n\n Severe renal damage \n\n Severe liver damage \n\n Acute myocardial infarction",
  "metadata": {
    "brief_title": "A Morbidity-Mortality and Remodeling Study With Valsartan",
    "phase": "Phase 4",
    "drugs": "['valsartan']",
    "drugs_list": [
      "valsartan"
    ],
    "diseases": "['Hypertension', 'Ischemic Heart Disease', 'Congestive Heart Failure']",
    "diseases_list": [
      "Hypertension",
      "Ischemic Heart Disease",
      "Congestive Heart Failure"
    ],
    "enrollment": "3000.0",
    "inclusion_criteria": "inclusion criteria: \n\n Clinical diagnosis of hypertension, ischemic heart disease and congestive heart failure \n\n ",
    "exclusion_criteria": ": \n\n Pregnancy \n\n Severe renal damage \n\n Severe liver damage \n\n Acute myocardial infarction",
    "brief_summary": "The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker (ARB), in addition to conventional treatment, will improve the prognosis of 3000 Japanese patients with cardiovascular diseases."
  }
}